Monday, June 6, 2011

Adoption of infection surveillance technology linked to better infection control practices


A recent study published in the American Journal of Infection Control looked at the relationship between the use of automated surveillance technology (AST) and the depth of implementation of evidence-based infection prevention and control practices.  The study analyzed survey responses from 241 acute care hospitals in California on questions related to the adoption of AST, the breadth and depth of implementation of HAI and process specific infection control practices. 

The study found a positive relationship between AST adoption and the adoption of infection control practices.  Although it’s unclear whether adoption of AST leads to better implementation of infection control practices or vice versa, it is clear that hospitals using AST are doing a better job implementing evidence-based infection control practices compared with hospitals that still rely on manual surveillance.    

Tuesday, May 24, 2011

Using Google to Track MRSA


It’s hard to believe it’s been nearly 3 years since Google launched its Flu Trends site. Flu Trends uses Google search queries to forecast outbreaks of influenza. The simplest example is trending total queries for "flu" over time to see if there are patterns indicating an outbreak. Google’s results found strong correlation between its search-based forecasts and CDC’s actual surveillance data.

Now, a group of out of University of Chicago has used the same approach to forecast MRSA outbreaks. Google search terms for “MRSA” and “staph” were used to predict MRSA hospitalization rate. Like Flu Trends, the MRSA predictor showed strong correlation between predicted and actual outcomes. If subsequent validations hold, Google search trends could be used as a proxy for hospital-reported data to support MRSA surveillance.

Monday, May 23, 2011

Biotech fills Pharma gap

antibiotics


A recent article in Bloomberg Business Week says that only two of the top 6 drugmakers (as determined by market value) are developing antibiotics. As IPs and pharmacists, many of our readers are already well aware of this neglected area of development. The void in the market has created an opportunity for sufficiently innovative competitors, and biotechnology companies are getting into the business as a result.

Big pharma has been getting out of the antibiotics business because the revenue potential for antibiotics is significantly lower than for medications used to treat chronic illness. Antibiotics are used in limited courses for several weeks at a time, as opposed to medicines that are used to treat chronic conditions over long periods. Additionally, as Bloomberg Business Week notes, doctors are advised to limit use of antibiotics because of concerns that overuse can cause resistance. Both these factors have a negative effect on antibiotic sales, removing the motivation for big pharma companies to develop new antibiotics. (It's worth noting that the concern about drug resistance is a well-founded one; drug-resistant bacteria cost the US healthcare system more than $34 billion and 100,000 lives last year, according to the Infection Disease Society of America, as cited by Bloomberg Business Week.)

We’ve previously written about the shortage of new antibiotic development on this blog, particularly as relates to NDM-1, and it’s comforting to know that some companies are trying to fill the general void. Bloomberg mentions Optimer Pharmaceuticals Inc. as an example of a biotech company developing an antibiotic. Optimer’s Dificid, developed to treat Clostridium difficile infections, could potentially be approved by the FDA by the end of this month. If so, it would be the first drug approved to treat C. diff in 25 years.

Other companies mentioned in the article are Trius Therapeutics, The Medicines Co., Paratek Pharmaceuticals Inc., Cubist Pharmaceuticals Inc., and Durata Therapeutics. All are in final testing of antibiotics that would be submitted for FDA approval in the next two to three years. While it’s certainly good to develop new lines of attack for bugs that are resistant to current antibiotics, it definitely does not diminish the need for vigilance when prescribing the currently existing drugs.

Article in Bloomberg Business Week: http://www.businessweek.com/news/2011-05-17/drug-resistant-germs-lure-biotechs-to-create-new-antibiotics.html

Friday, May 13, 2011

The Tyranny of Zero Tolerance

Think about the most complicated infection control patient you have ever had. My worst patient was admitted with necrotizing fasciitis that had eroded almost the full circumference of of her trunk and spread to her perineal area. Naturally, she had an indwelling urinary catheter and several central lines. Her wounds were constantly draining and she was able to spend, at most, an hour a day out of bed. Our goal was to keep her from acquiring both a BSI and an SSI. She was with us about 2 months before she acquired each type of infection.

Zero tolerance is generally accepted as the mantra for demonstrating commitment to reducing HAIs. According to APIC zero tolerance generally means that no one on a healthcare team believes that even one HAI is acceptable. The assumption is that zero tolerance will eventually result in zero HAIs.

The zero tolerance approach represents a shift from believing HAIs as a normal risk of hospitalization. Certainly no one wants to go back to that way of thinking. But is zero tolerance realistic? Does it support the culture of blame that many quality officers are trying to eliminate?

We all know that healthcare is a complicated service compounded by the fact that peoples’ bodies break down, including their immune systems. Was it realistic to think we could prevent our patient from getting HAIs given the massive assault on her body from her first infection? Good nursing care during her admission resulted in a reduction of her initial wounds to about half of their original size. Unfortunately, the initial infection was not treatable and it spread to other sites despite aggressive care. It was at the time of that spread that the other infections occurred.

If I had strictly ascribed to the zero tolerance policy, my course of action would have been to conduct quality analyses and try to determine which staff performed poorly and/or what they had done that was wrong. That would have been followed by remedial actions including the possibility of staff discipline.

But in this case I believed that the concept of zero tolerance was not appropriate. There seemed no point in discussing the infection prevention strategies that might have been breached. The staff were familiar with prevention strategies. They were devastated when the HAIs developed. Reviewing prevention strategies or threatening punishment would have been viewed as a punishment and, I believe, a disincentive for future prevention efforts.

The question was whether, given this patient's underlying condition, any prevention strategies would have been successful? The answer was probably not. So I wondered what the teachable moment would be directed toward. I wondered if there was anything positive that could be taken from this situation. It occurred to me that, given the massiveness of the patient's initial infection, what the staff had done was to prevent HAIs for a relatively extended period of time. They had taken the necessary infection control precautions that were successful until the patient’s immune system was overwhelmed.

Is there a place for zero tolerance? Yes, but not as an inviolate goal. To hold that belief without allowing different perspectives may be detrimental to prevention efforts. Sometimes we must give ourselves credit for keeping patients infection-free for as long as possible given the forces that both patients and staff are fighting against. Supporting staff even in the face of failure can be an effective way to reinforce good practice for the many other patients whose conditions will challenge our best efforts.

Thursday, April 28, 2011

Watch out for Armadillos!

armadillo"


Research released today in the New England Journal of Medicine points to what many leprosy researchers have suspected for years: that armadillos can likely transmit leprosy to humans.

Leprosy, also called Hansen ’s disease, is caused by Mycobacterium leprae. The bug likes cooler temperatures than are found at the cores of human bodies, which is why it infects our extremities and skin. Armadillos have a low core body temperature, about 89 degrees Fahrenheit, which Mycobacterium leprae finds quite comfortable.

How did armadillos, of all creatures, get leprosy? Humans gave it to them. Richard Truman, the study’s first author, tells NPR health blog “Shots” that leprosy was brought to the New World by European settlers. It’s not known exactly how or when we gave it to the armadillos, but now about 15% of them carry the disease.

The study looked at the genetics of the bacterial strains found in leprosy patients in the southern U.S., and compared them with the genetics of the bacteria from wild armadillos living in the same area. A majority of both the patients and the armadillos carried the same strain of bacteria, and this strain hasn’t been reported anywhere else in the world. The conclusion is that the patients got leprosy from the armadillos.

Truman tells NPR that the risk of contracting leprosy from brief contact with an armadillo is low, so how did they give it to us? In some southern states, barbecued armadillo and armadillo chili are folk favorites. That’s right; the humans got leprosy from eating armadillo. Fortunately, if treated early with antibiotics, the bacteria are eradicated from the body and people become healthy again. Nonetheless, I don’t think you’ll catch me ordering up an armadillo burger anytime soon.

New England Journal of Medicine article: http://www.nejm.org/doi/full/10.1056/NEJMoa1010536

NPR "Shots" blog post: http://www.npr.org/blogs/health/2011/04/28/135740951/mysterious-leprosy-cases-linked-to-armadillos

Monday, April 25, 2011

FDA warns makers of hand sanitizers on false claims

The FDA sent warning letters to four manufacturers of over-the-counter hand sanitizer products that claim to prevent infection from MRSA, H1N1, and E. coli.  The FDA found insufficient data to support the claims made by these companies regarding their products and considers their labeling a violation of federal law.
 
The four companies and their products are:
  • Tec Laboratories for Staphaseptic First Aid Antiseptic/Pain Relieving Gel
  • JD Nelson and Associates for Safe4Hours Hand Sanitizing Lotion and Safe4Hours First Aid Antiseptic Skin Protectant
  • Dr. G.H. Tichenor Antiseptic Co. for Dr. Tichenor’s Antiseptic Gel
  • Oh So Clean, Inc dba CleanWell Company for CleanWell All-Natural Foaming Hand Sanitizer, CleanWell All-Natural Hand Sanitizer, CleanWell All-Natural Hand Sanitizing Wipes, and CleanWell All-Natural Antibacterial Foaming Handsoap
Major concerns cited in FDA's letters were:
1.  The manufacturer's claims about the effectiveness of the products fall under the FDA drug category.  FDA defines drugs as anything that cures, mitigates, treats or prevents disease. None of the products have been approved by FDA as drugs.
2.  Some products are defined as new drugs because the combination of ingredients included in the product do not match any similar product that has been approved by FDA as a drug.
3.  Several do not have sufficient details about the ingredients.  FDA requires that the name, quantity and proportion of each ingredient be listed on the label.  The lists must match all product marketing materials.
4.  One citation indicated that a product has a combination of ingredients that have not been tested by FDA in combination.  That is, each ingredient has been found safe alone but not in combination with other ingredients.  However, a troubling citation is a citation for a product that contains Triclosan.  Triclosan has not yet received FDA widespread approval for safety.  The other products contain ingredients that are probably harmless, if not effective, but this product may contain ingredients that are harmful.
5.  Three of the four manufacturers have been notified that they need to respond to the FDA within 15 days of the letter with plans to come into compliance.  In some cases, formal requests for FDA approval are necessary.  However, in others only re-labeling may be necessary.
6.  FDA has ordered the manufacturer of  CleanWell All Natural Foaming Hand Sanitizer to stop producing their product(s).  This company was cited in 2010 for FDA violations and their response has not been approved by FDA.  Their response included "technology" briefs intended to show scientific proof of efficacy.  These have been denied by FDA.  Finally, this company was cited for lack of quality control of the manufacturing process and states that the product may be subject to adulteration because of this.

 So what to look for in a sanitizer?  We recommend a sanitizer that contains at least 61% alcohol and has been approved by the FDA.  Also, look for sanitizers with lotion in them since alcohol alone makes the skin very dry.  

Friday, April 22, 2011

Updates from NHSN

Updates from NHSN about HAI Reporting

I recently returned from the SHEA conference where I attended as many sessions as I could that dealt with NHSN’s thoughts about current or future reporting. You will be happy to know that someone has heard IP’s cries of pain when it comes to the amount of time that we spend on data collection! Here are some of the specific messages from the forums I attended.

The overall theme was that NHSN has a mandate (that they call their Action Plan) to reduce the time, effort and money spent on surveillance. They spoke several times about the need to (a) provide definitions that will track the effects of interventions, (b) will have clinical as well as surveillance meaning, and (c) will give IPs more time on clinical units helping patients and staff to improve care.

They will be issuing a new SSI form as soon as OMB approves it. They have changed the form so required data is more relevant to specific surgeries. For instance, information about implants will be required for orthopedic procedures but not for hysterectomies.

NHSN is currently having consensus meetings to finalize the criteria for VAP. They expect to have a statement by mid-summer. It will then take them some time to develop the software for NHSN submission. They expect that VAP reporting will become “mandatory” no sooner than January 1, 2013.

The biggest changes they are considering related to the definition of VAP include:

- making the chest x-ray a confirmatory finding rather than a key criterion of the definition,

-specifying PEEP settings and FiO2 readings as the specific indicators for worsening gas exchange, and

- specifying the time on a vent at 4 or more days before considering pneumonia as a possibility.

The SHEA forums with NHSN content were very satisfying. For the first time in memory the phrase “I’m the government and I’m here to help” wasn’t the introductory joke of the sessions.

"I Watch the Line" selected to be shown at the APIC Film Festival

The APIC Film Festival committee notified us yesterday that Ron's music video, "I Watch the Line," has been selected to be shown at the APIC Film Festival.  The Film Festival will take place during the Annual APIC Conference from June 27 to June 29 in Baltimore, MD.

Monday, April 18, 2011

New Partnership for Patients aims to improve care, reduce cost


The federal government took a step towards sustainable healthcare this month by launching a new initiative to reduce preventable errors in hospitals.  The Partnership for Patients: Better Care, Lower Costs aims to achieve $10 million in health care savings over the next three years. 

The two key objectives of the partnership are to:
  • Keep patients from getting injured or sicker by reducing preventable hospital-acquired conditions by 40% by 2013.  Achieving this goal would mean approximately 1.8 million fewer injuries to patients and more than 60,000 lives saved over three years.
  • Help patients heal without complications by reducing hospital readmissions by 20% by 2013.  Achieving this goal would mean more than 1.6 million patients would recover from illness without suffering a preventable complication requiring re-hospitalization within 30 days of discharge.
The partnership will bring together leaders from hospitals and state and federal governments to devise strategies to achieve these objectives.  The details of the partnership are still being worked out so stay tuned!